Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
ConclusionsNivolumab plus ipilimumab as first-line treatment could gain more health benefits for advanced RCC in comparison with standard sunitinib, which is considered to be cost-effective in the US and China but not in the UK.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Study | Toxicology | UK Health | USA Health | Yervoy